Pruritus and Tense Bullae After Discontinuation of Pembrolizumab in a Patient With Renal Cell Carcinoma | Dermatology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Pruritus and Tense Bullae After Discontinuation of Pembrolizumab in a Patient With Renal Cell Carcinoma

Educational Objective
Based on this clinical scenario and the accompanying image, understand how to arrive at a correct diagnosis.
1 Credit CME

Please finish quiz first before checking answer.

You answered correctly!

Read the answer below and download your certificate.

You answered incorrectly.

Read the discussion below and retake the quiz.

Survey Complete!

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Kristen Lo Sicco, MD, New York University Grossman School of Medicine, 240 E 38th St, 11th Floor, New York, NY 10016 (Kristen.Losicco@nyulangone.org).

Published Online: September 14, 2020. doi:10.1001/jama.2020.10159

Conflict of Interest Disclosures: None reported.

Additional Contributions: We thank our dermatopathology colleagues Nooshin Brinster, MD, and Shane Meehan, MD (Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine), who read the hematoxylin-eosin and direct immunofluorescence specimens. Neither of these individuals received any compensation for their contributions. We thank the patient for providing permission to share her information.

References
1.
Wang  LL , Patel  G , Chiesa-Fuxench  ZC ,  et al.  Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy.   JAMA Dermatol. 2018;154(9):1057-1061. doi:10.1001/jamadermatol.2018.1912PubMedGoogle ScholarCrossref
2.
Joly  P , Roujeau  JC , Benichou  J ,  et al; Bullous Diseases French Study Group.  A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.   N Engl J Med. 2002;346(5):321-327. doi:10.1056/NEJMoa011592PubMedGoogle ScholarCrossref
3.
Kayani  M , Aslam  AM .  Bullous pemphigoid and pemphigus vulgaris.   BMJ. 2017;357:j2169. doi:10.1136/bmj.j2169PubMedGoogle ScholarCrossref
4.
Bernard  P , Antonicelli  F .  Bullous pemphigoid: a review of its diagnosis, associations and treatment.   Am J Clin Dermatol. 2017;18(4):513-528. doi:10.1007/s40257-017-0264-2PubMedGoogle ScholarCrossref
5.
Lopez  AT , Khanna  T , Antonov  N , Audrey-Bayan  C , Geskin  L .  A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.   Int J Dermatol. 2018;57(6):664-669. doi:10.1111/ijd.13984PubMedGoogle ScholarCrossref
6.
Nelson  CA , Singer  S , Chen  T , Puleo  AE , Lian  CG , Wei  EX ,  et al.  Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes.   J Am Acad Dermatol. Published online January 20, 2020. doi:10.1016/j.jaad.2019.12.068Google Scholar
7.
Adachi  E , Honda  T , Nonoyama  S ,  et al.  Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.   J Dermatol. 2019;46(7):e232-e233. doi:10.1111/1346-8138.14813PubMedGoogle Scholar
8.
Carlos  G , Anforth  R , Chou  S , Clements  A , Fernandez-Peñas  P .  A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.   Melanoma Res. 2015;25(3):265-268. doi:10.1097/CMR.0000000000000155PubMedGoogle ScholarCrossref
9.
Sun  CW , Grossman  SK , Aphale  A , Hsu  S .  Pembrolizumab-induced bullous pemphigoid.   JAAD Case Rep. 2019;5(4):362-364. doi:10.1016/j.jdcr.2019.02.008PubMedGoogle ScholarCrossref
10.
Kremer  N , Snast  I , Cohen  ES ,  et al.  Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature.   Am J Clin Dermatol. 2019;20(2):209-216. doi:10.1007/s40257-018-0401-6PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close